Zenas Biopharma, INC Form 4 insider transactions

Director Jason Nunn was granted 18,500 stock options in Zenas BioPharma, Inc. with an exercise price of $18.71.

Director Lu Hongbo was granted 18,500 stock options in Zenas BioPharma, Inc. with an exercise price of $18.71.

Zenas BioPharma CEO Leon O. Moulder Jr. was granted 500,000 stock options with an exercise price of $18.71.

Director John J. Orloff was granted 18,500 stock options in Zenas BioPharma, Inc. with an exercise price of $18.71.

Lisa von Moltke, Head of R&D and CMO of Zenas BioPharma, was granted 150,000 stock options with an exercise price of $18.71.

Director Patricia L. Allen was granted 18,500 stock options in Zenas BioPharma, Inc. as part of a standard equity compensation plan.

Director James P. Boylan was granted 18,500 stock options in Zenas BioPharma, Inc. as disclosed in a recent SEC Form 4 filing.

Director Patrick G. Enright was granted 18,500 stock options in Zenas BioPharma, Inc. with an exercise price of $18.71.

President and COO Joseph L. Farmer acquired common stock via ESPP and received a stock option grant for 175,000 shares.

Zenas BioPharma CFO Jennifer Fox acquired 1,592 shares via an employee stock plan and was granted 125,000 stock options.

Zenas BioPharma CEO Leon O. Moulder Jr. purchased 60,000 shares of common stock at a weighted average price of $16.88.

CEO Leon O. Moulder, Jr. purchased 60,000 shares of Zenas BioPharma, Inc. common stock through Tellus BioVentures LLC.

Director Lu Hongbo acquired 3,768 shares of Zenas BioPharma common stock on March 31, 2026, for $18.63 per share.

Fairmount Funds Management LLC and related entities plan to acquire 150,000 shares of Zenas BioPharma common stock at $20 per share on March 31, 2026, under a Rule 10b5-1 plan.

Zenas BioPharma's CEO and Chairman, Leon O. Moulder Jr., increased his beneficial ownership by purchasing 54,000 shares of common stock in late March 2026.

Zenas BioPharma Director and 10% owner Hongbo Lu acquired 75,000 shares of common stock at $20.00 per share in a public offering.

Zenas BioPharma Director Hongbo Lu reported an indirect purchase of 25,985 shares of common stock at $22.5 per share.

Zenas BioPharma Director Patricia L. Allen acquired 19,860 shares of common stock across multiple transactions in mid-February 2026, increasing her direct beneficial ownership.

Zenas BioPharma's CEO, Leon O. Moulder, Jr., acquired 100,000 shares of common stock over three days in early January 2026, totaling approximately $1.6 million.

Zenas BioPharma Director Jason Raleigh Nunn indirectly acquired 63,158 shares of common stock from the issuer at $19 per share, totaling approximately $1.2 million.

SR One Capital Management and Simeon George increased their beneficial ownership in Zenas BioPharma, Inc. by purchasing common stock at $19 per share.

Zenas BioPharma director Patrick G. Enright and affiliated entities acquired common stock totaling 117,255 shares through a private offering on October 9, 2025.

Zenas BioPharma's CEO and Chairman, Leon O. Moulder Jr., acquired 36,928 shares of common stock at $20.85 per share through a trust, increasing his indirect beneficial ownership.

Fairmount Funds Management LLC and related entities increased their beneficial ownership in Zenas BioPharma, Inc. by purchasing 316,219 shares of common stock at $19 per share.

Zenas BioPharma Director Hongbo Lu, through affiliated entities, reported significant indirect purchases of common stock totaling 321,983 shares across two transactions.

Zenas BioPharma, Inc. director Jason Raleigh Nunn was granted 18,500 stock options with an exercise price of $11.94, vesting fully on June 10, 2026.

Jennifer A. Fox, Chief Financial Officer and Chief Business Officer of Zenas BioPharma, Inc., was granted 150,000 stock options at an exercise price of $11.94 per share.

Zenas BioPharma, Inc. has granted 100,000 stock options to its Chief Commercial Officer, Orlando Oliveira, with an exercise price of $11.94 per share, vesting over four years.

Zenas BioPharma, Inc. Director James P. Boylan was granted 18,500 stock options with an exercise price of $11.94 per share, vesting on June 10, 2026.

Zenas BioPharma, Inc. Director Patricia L. Allen was granted 18,500 stock options with an exercise price of $11.94, vesting fully on June 10, 2026.